img

Neoantigen Cancer Vaccine Industry: Global Market Opportunities and Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 432 | Industry : Medical Care

Publisher : MRG | Format : PDF

Neoantigen Cancer Vaccine Industry: Global Market Opportunities and Forecast 2024-2034

This report provides a comprehensive analysis of current global Neoantigen Cancer Vaccine market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Neoantigen Cancer Vaccine industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

According to this survey, the global Neoantigen Cancer Vaccine market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Neoantigen Cancer Vaccine Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Neoantigen Cancer Vaccine market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

The Global Neoantigen Cancer Vaccine Market has been exhibited in detail in the following chapters
Chapter 1 displays the basic product introduction and market overview.
Chapter 2 provides the competition landscape of global Neoantigen Cancer Vaccine industry.
Chapter 3 provides the market analysis by type and by region
Chapter 4 provides the market analysis by application and by region
Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
Chapter 12 provides the market forecast by type and by application
Chapter 13 provides the market forecast by region
Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
Chapter 15 conclusions

Segmented by Type
Personalized Vaccine
Off-the-shelf Neovaccines

Segmented by Application
Hospital
Clinic
Others

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
Vaccibody
Roche
OSE Immunotherapeutics
Nouscom
Neon Therapeutics
Merck
Medimmune
Medigene
Gritstone Oncology
Genocea
Geneos Therapeutics
Brightpath Biotherapeutics
Agenus
Advaxis


Table of Content

Table of Contents

1 Product Introduction and Overview
1.1 Product Definition
1.2 Product Specification
1.3 Global Market Overview
1.3.1 Global Neoantigen Cancer Vaccine Market Status and Forecast (2016-2027)
1.3.2 Global Neoantigen Cancer Vaccine Sales Value CAGR by Region
1.4 Market Drivers, Inhibitors
1.4.1 Market Drivers
1.4.2 Market Inhibitors
1.4.3 COVID-19 Impact Analysis
2 Global Neoantigen Cancer Vaccine Supply by Company
2.1 Global Neoantigen Cancer Vaccine Sales Value by Company
2.2 Neoantigen Cancer Vaccine Sales Area of Main Manufacturers
2.3 Trend of Concentration Rate
3 Global and Regional Neoantigen Cancer Vaccine Market Status by Type
3.1 Neoantigen Cancer Vaccine Type Introduction
3.1.1 Personalized Vaccine
3.1.2 Off-the-shelf Neovaccines
3.2 Global Neoantigen Cancer Vaccine Market by Type
3.3 North America: by Type
3.4 Europe: by Type
3.5 Asia Pacific: by Type
3.6 Central & South America: by Type
3.7 Middle East & Africa: by Type
4 Global and Regional Neoantigen Cancer Vaccine Market Status by Application
4.1 Neoantigen Cancer Vaccine Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Neoantigen Cancer Vaccine Market by Application
4.3 North America: by Application
4.4 Europe: by Application
4.5 Asia Pacific: by Application
4.6 Central & South America: by Application
4.7 Middle East & Africa: by Application
5 Global Neoantigen Cancer Vaccine Market Status by Region
5.1 Global Neoantigen Cancer Vaccine Market by Region
5.2 North America Neoantigen Cancer Vaccine Market Status
5.3 Europe Neoantigen Cancer Vaccine Market Status
5.4 Asia Pacific Neoantigen Cancer Vaccine Market Status
5.5 Central & South America Neoantigen Cancer Vaccine Market Status
5.6 Middle East & Africa Neoantigen Cancer Vaccine Market Status
6 North America Neoantigen Cancer Vaccine Market Status
6.1 North America Neoantigen Cancer Vaccine Market by Country
6.2 United States
6.3 Canada
6.4 Mexico
7 Europe Neoantigen Cancer Vaccine Market Status
7.1 Europe Neoantigen Cancer Vaccine Market by Country
7.2 Germany
7.3 France
7.4 UK
7.5 Italy
7.6 Russia
7.7 Spain
8 Asia Pacific Neoantigen Cancer Vaccine Market Status
8.1 Asia Pacific Neoantigen Cancer Vaccine Market by Country
8.2 China
8.3 Japan
8.4 Korea
8.5 Southeast Asia
8.6 India
8.7 Australasia
9 Central & South America Neoantigen Cancer Vaccine Market Status
9.1 Central & South America Neoantigen Cancer Vaccine Market by Country
9.2 Brazil
9.3 Argentina
9.4 Colombia
10 Middle East & Africa Neoantigen Cancer Vaccine Market Status
10.1 Middle East & Africa Neoantigen Cancer Vaccine Market by Country
10.2 Iran
10.3 Israel
10.4 Turkey
10.5 South Africa
10.8 Saudi Arabia
11 Major Downstream Customers Analysis
11.1 Customer One Analysis
11.2 Customer Two Analysis
11.3 Customer Three Analysis
11.4 Customer Four Analysis
12 Global Neoantigen Cancer Vaccine Market Forecast by Type and by Application
12.1 Global Neoantigen Cancer Vaccine Sales Value Forecast (2022-2027)
12.2 Global Neoantigen Cancer Vaccine Forecast by Type
12.3 Global Neoantigen Cancer Vaccine Forecast by Application
13 Global Neoantigen Cancer Vaccine Market Forecast by Region/Country
13.1 Global Neoantigen Cancer Vaccine Market Forecast by Region (2022-2027)
13.2 North America Market Forecast
13.3 Europe Market Forecast
13.4 Asia Pacific Market Forecast
13.5 Central & South America Market Forecast
13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
14.1 Vaccibody
14.1.1 Company Information
14.1.2 Neoantigen Cancer Vaccine Product Introduction
14.1.3 Vaccibody Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.1.4 SWOT Analysis
14.2 Roche
14.2.1 Company Information
14.2.2 Neoantigen Cancer Vaccine Product Introduction
14.2.3 Roche Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.2.4 SWOT Analysis
14.3 OSE Immunotherapeutics
14.3.1 Company Information
14.3.2 Neoantigen Cancer Vaccine Product Introduction
14.3.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.3.4 SWOT Analysis
14.4 Nouscom
14.4.1 Company Information
14.4.2 Neoantigen Cancer Vaccine Product Introduction
14.4.3 Nouscom Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.4.4 SWOT Analysis
14.5 Neon Therapeutics
14.5.1 Company Information
14.5.2 Neoantigen Cancer Vaccine Product Introduction
14.5.3 Neon Therapeutics Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.5.4 SWOT Analysis
14.6 Merck
14.6.1 Company Information
14.6.2 Neoantigen Cancer Vaccine Product Introduction
14.6.3 Merck Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.6.4 SWOT Analysis
14.7 Medimmune
14.7.1 Company Information
14.7.2 Neoantigen Cancer Vaccine Product Introduction
14.7.3 Medimmune Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.7.4 SWOT Analysis
14.8 Medigene
14.8.1 Company Information
14.8.2 Neoantigen Cancer Vaccine Product Introduction
14.8.3 Medigene Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.8.4 SWOT Analysis
14.9 Gritstone Oncology
14.9.1 Company Information
14.9.2 Neoantigen Cancer Vaccine Product Introduction
14.9.3 Gritstone Oncology Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.9.4 SWOT Analysis
14.10 Genocea
14.10.1 Company Information
14.10.2 Neoantigen Cancer Vaccine Product Introduction
14.10.3 Genocea Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
14.10.4 SWOT Analysis
14.11 Geneos Therapeutics
14.12 Brightpath Biotherapeutics
14.13 Agenus
14.14 Advaxis
15 Conclusion
16 Methodology

List of Figure

List of Tables

Table Global Neoantigen Cancer Vaccine Sales Value (Million USD) and CAGR by Region (2016-2027)
Table Global Neoantigen Cancer Vaccine Sales Value (Million USD) by Company (2019-2021)
Table Global Neoantigen Cancer Vaccine Sales Value Market Share by Company (2019-2021)
Table Main Manufacturers Neoantigen Cancer Vaccine Sales Area
Table Neoantigen Cancer Vaccine Market Concentration (Top 3, Top 5) (2019-2021)
Table Global Neoantigen Cancer Vaccine Sales Value (Million USD) by Type (2016-2021)
Table Global Neoantigen Cancer Vaccine Sals Value Market Share by Type (2016-2021)
Table North America Neoantigen Cancer Vaccine Sales Value (Million USD) by Type (2016-2021)
Table North America Neoantigen Cancer Vaccine Sales Value Market Share by Type (2016-2021)
Table Europe Neoantigen Cancer Vaccine Sales Value (Million USD) by Type (2016-2021)
Table Europe Neoantigen Cancer Vaccine Sales Value Market Share by Type (2016-2021)
Table Asia Pacific Neoantigen Cancer Vaccine Sales Value (Million USD) by Type (2016-2021)
Table Asia Pacific Neoantigen Cancer Vaccine Sales Value Market Share by Type (2016-2021)
Table Central & South America Neoantigen Cancer Vaccine Sales Value (Million USD) by Type (2016-2021)
Table Central & South America Pacific Neoantigen Cancer Vaccine Sales Value Market Share by Type (2016-2021)
Table Middle East & Africa Neoantigen Cancer Vaccine Sales Value (Million USD) by Type (2016-2021)
Table Middle East & Africa Neoantigen Cancer Vaccine Sales Value Market Share by Type (2016-2021)
Table Global Neoantigen Cancer Vaccine Sales Value (Million USD) by Application (2016-2021)
Table Global Neoantigen Cancer Vaccine Value Market Share by Application (2016-2021)
Table North America Neoantigen Cancer Vaccine Sales Value (Million USD) by Application (2016-2021)
Table North America Neoantigen Cancer Vaccine Sales Value Market Share by Application (2016-2021)
Table Europe Neoantigen Cancer Vaccine Sales Value (Million USD) by Application (2016-2021)
Table Europe Neoantigen Cancer Vaccine Sales Value Market Share by Application (2016-2021)
Table Asia Pacific Neoantigen Cancer Vaccine Sales Value (Million USD) by Application (2016-2021)
Table Asia Pacific Neoantigen Cancer Vaccine Sales Value Market Share by Application (2016-2021)
Table Central & South America Neoantigen Cancer Vaccine Sales Value (Million USD) by Application (2016-2021)
Table Central & South America Pacific Neoantigen Cancer Vaccine Sales Value Market Share by Application (2016-2021)
Table Middle East & Africa Neoantigen Cancer Vaccine Sales Value (Million USD) by Application (2016-2021)
Table Middle East & Africa Neoantigen Cancer Vaccine Sales Value Market Share by Application (2016-2021)
Table Global Neoantigen Cancer Vaccine Sales Value (Million USD) by Region (2016-2021)
Table Global Neoantigen Cancer Vaccine Value Market Share by Region (2016-2021)
Table North America Neoantigen Cancer Vaccine Sales Value (Million USD) by Country (2016-2021)
Table North America Neoantigen Cancer Vaccine Value Market Share by Country (2016-2021)
Table Europe Neoantigen Cancer Vaccine Sales Value (Million USD) by Country (2016-2021)
Table Europe Neoantigen Cancer Vaccine Value Market Share by Country (2016-2021)
Table Asia Pacific Neoantigen Cancer Vaccine Sales Value (Million USD) by Country (2016-2021)
Table Asia Pacific Neoantigen Cancer Vaccine Value Market Share by Country (2016-2021)
Table Central & South America Neoantigen Cancer Vaccine Sales Value (Million USD) by Country (2016-2021)
Table Central & South America Neoantigen Cancer Vaccine Value Market Share by Country (2016-2021)
Table Middle East & Africa Neoantigen Cancer Vaccine Sales Value (Million USD) by Country (2016-2021)
Table Middle East & Africa Neoantigen Cancer Vaccine Value Market Share by Country (2016-2021)
Table Global Neoantigen Cancer Vaccine Value (Million USD) Forecast by Type (2022-2027)
Table Global Neoantigen Cancer Vaccine Value Market Share Forecast by Type (2022-2027)
Table Global Neoantigen Cancer Vaccine Value (Million USD) Forecast by Application (2022-2027)
Table Global Neoantigen Cancer Vaccine Value Market Share Forecast by Application (2022-2027)
Table Global Neoantigen Cancer Vaccine Value (Million USD) Forecast by Region (2022-2027)
Table Global Neoantigen Cancer Vaccine Value Market Share Forecast by Region (2022-2027)
Table Vaccibody Company Information
Table Vaccibody Product Introduction
Table Vaccibody Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table Roche Company Information
Table Roche Product Introduction
Table Roche Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table OSE Immunotherapeutics Company Information
Table OSE Immunotherapeutics Product Introduction
Table OSE Immunotherapeutics Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table Nouscom Company Information
Table Nouscom Product Introduction
Table Nouscom Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table Neon Therapeutics Company Information
Table Neon Therapeutics Product Introduction
Table Neon Therapeutics Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table Merck Company Information
Table Merck Product Introduction
Table Merck Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table Medimmune Company Information
Table Medimmune Product Introduction
Table Medimmune Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table Medigene Company Information
Table Medigene Product Introduction
Table Medigene Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table Gritstone Oncology Company Information
Table Gritstone Oncology Product Introduction
Table Gritstone Oncology Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)
Table Genocea Company Information
Table Genocea Product Introduction
Table Genocea Neoantigen Cancer Vaccine Sales Value, Gross Margin and Global Share (2019-2021)

Select User License

$2900 Single Licence
$4700 Enterprise Licence
$5700 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries